[1]张燕,冯劼,鲁铭,等.康柏西普在糖尿病性白内障患者超声乳化术中的应用[J].眼科新进展,2019,39(11):1052-1055.[doi:10.13389/j.cnki.rao.2019.0241]
　ZHANG Yan,FENG Jie,LU Ming,et al.Intravitreal injection of Conbercept during phacoemulsification for diabetic cataract[J].Recent Advances in Ophthalmology,2019,39(11):1052-1055.[doi:10.13389/j.cnki.rao.2019.0241]
点击复制

康柏西普在糖尿病性白内障患者超声乳化术中的应用/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
39卷
期数:
2019年11期
页码:
1052-1055
栏目:
应用研究
出版日期:
2019-11-05

文章信息/Info

Title:
Intravitreal injection of Conbercept during phacoemulsification for diabetic cataract
作者:
张燕; 冯劼; 鲁铭; 金翼; 罗艳; 江城
430022　湖北省武汉市，武汉市第一医院眼科（张燕，冯劼，鲁铭，金翼，罗艳）；430022　湖北省武汉市，武汉市第一医院盘龙综合内科（江城）
Author(s):
ZHANG Yan; FENG Jie; LU Ming; JIN Yi; LUO Yan; JIANG Cheng
Department of Ophthalmology，the First Hospital of Wuhan(ZHANG Yan，FENG Jie，LU Ming，JIN Yi，LUO Yan)，Wuhan 430022，Hubei Province，China；Department of Panlong General Medicine Center，the First Hospital of Wuhan(JIANG Cheng)，Wuhan 430022，Hubei Province，China
关键词:
康柏西普; 白内障超声乳化; 糖尿病性白内障; 黄斑中心凹视网膜厚度
Keywords:
Conbercept; phacoemulsification; diabetic cataract; foveal retinal thickness
分类号:
R776
DOI:
10.13389/j.cnki.rao.2019.0241
文献标志码:
A
摘要:
目的　探讨白内障超声乳化术中注射康柏西普在糖尿病性白内障治疗中的效果。方法　选取2015年7月至2017年5月于我院就诊的糖尿病性白内障患者74例（74眼）为研究对象，按治疗方法不同分为对照组38例（单纯行白内障超声乳化手术）及治疗组36例［白内障超声乳化术中予以玻璃体内注射康柏西普0.05 mL（2.5 mg）］。记录并对比两组患者术前及术后1周、1个月、3个月、6个月的最佳矫正视力(best corrected visual acuity,BCVA)、黄斑中心凹视网膜厚度（foveal retinal thickness,FRT）及术后并发症发生情况。结果　治疗组及对照组术后不同时间点BCVA均较术前有不同程度提高（均为P<0.05），术后1周、1个月两组BCVA相比差异均有统计学意义（均为P<0.05）。术后1周、1个月，治疗组FRT分别为（214.694±36.358）μm及（219.417±34.925）μm，均较术前（247.944±50.508）μm降低（均为P<0.05）；对照组术后1周及1个月FRT分别为（253.105±46.635）μm及（260.395±68.718）μm，均较术前（245.553±48.653）μm有不同程度增加（均为P<0.05）；术后1周、1个月、3个月两组FRT相比差异均有统计学意义（均为P<0.05）。治疗组结膜下出血发生率较对照组高（P<0.05）。结论　白内障超声乳化术中予以玻璃体内注射康柏西普治疗糖尿病性白内障短期疗效好。
Abstract:
Objective　To evaluate the effects of intravitreal injection of Conbercept during phacoemulsification for diabetic cataract.Methods　Totally 74 patients (74 eyes) with diabetic cataract diagnosed in our hospital from July 2015 to May 2017 were divided into treatment group ［36 patients were treated with intravitreal injection of 0.05 mL (2.5 mg) Conbercept during phacoemulsification］ and control group (38 patients were treated with cataract phacoemulsification alone).The best corrected visual acuity (BCVA) and foveal retinal thickness（FRT）before operation,1 week,1 month,3 months and 6 months after operation were recorded and compared,and the complications were recorded.Results　The postoperative BCVA at all time points were higher than that before operation in the two groups (all P<0.05).FRT was (214.694±36.358)μm one week after operation and (219.417±34.925)μm one month post-operation in the treatment group,both which were significantly decreased when compared with before operation ［(247.944±50.508)μm］ (all P<0.05).FRT was (253.105±46.635)μm one week after operation and (260.395±68.718)μm one month post-operation in the control group,both which were increased when compared to before operation ［(245.553±48.653)μm］ (all P<0.05).There were significant differences in FRT between the two groups one week,one month,three months after operation (all P<0.05).The incidence rate of subconjunctival hemorrhage was higher in the treatment group than the control group (P>0.05).Conclusion　Intravitreal injection of Conbercept during phacoemulsification for diabetic cataract can achieve better short-term outcomes.

参考文献/References:

［1］　STRUCK H G，HEIDER C，LAUTENSCHLAGER C.Changes in the lens epithelium of diabetic and non-diabetic patients with various forms of opacities in senile cataract［J］.Klin Monatsbl Augenheilkd，2000，216(4)：204-209.
［2］　CUNLIFFE I A，FLANAGAN D W，GEORGE N D，AQQARWAAL R J，MOORE A T.Extracapsular cataract surgery with lens implantation in diabetics with and without proliferative retinopathy［J］.Br J Ophthalmol，1991，75(1)：9-12.
［3］　WELLS J A，GLADDMAN A R，AYALA A R，JAMPOLM L M，AIELLO L P，ANTOSZYK A N，et al.Aflibercept，bevacizumab or ranibizumab for diabetic macular edema［J］.N Engl J Med，2015，372(13)：1193-1203.
［4］　CHEN L J，HAO C Y，XU J X，CHEN J Y.Morbidity situation of macular edema in patients with diabetic cataract after phacoemulsification［J］.Chin Med Her，2016，13(1)：122-125.
陈丽娟，郝晨宇，徐晶晓，陈君宇.糖尿病性白内障患者超声乳化术后黄斑水肿的发病情况［J］.中国医药导报，2016，13（1）：122-125.
［5］　BRESSLER N M，VARMA R，SUNER I J，DOLAN C M，WARD J，EHRIJCH J S，et al.Vision-related function after ranibizumab treatment for diabetic macular edema.Results from RIDE and RISE［J］.Ophthalmology，2014，121(12)：2461-2472.
［6］　GROUP OF FUNDUS DISEASES，OPHTHALMOLOGICAL SOCIETY，CHINESE MEDICAL ASSOCIAYION.Guidelines for clinical diagnosis and treatment of diabetic retinopathy in China (2014)［J］.Chin J Ophathalmol，2014，50(11)：851-856.
中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南（2014年）［J］.中华眼科杂志，2014，50（11）：851-865.
［7］　NEPOMUCENO A B，TAKAKI E，PAES D E，ALMEIDA F P，PERONI R，CARDILLO J A，et al.A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema［J］.Am J Ophthalmol，2013，156(3)：502-510.
［8］　CHENG M Z，WANG C，CHEN M.Phacoemulsification combined with intravitreal injection of lucentis for diabetic cataract［J］.Rec Adv Ophthalmol，2016，36(8)：754-756.
程明智，王翠，陈明.超声乳化联合玻璃体内注射雷珠单抗治疗糖尿病性白内障的临床观察［J］.眼科新进展，2016，36(8)：754-756.
［9］　LIN W H,LU M，TANG H Y.Clinacal application of Ranibizumab in the therapy of diabetic cataract［J］.Int Eye Sci，2015，15(5)：880-882.
林为华，卢敏，唐浩英.雷珠单抗在糖尿病性白内障治疗中的临床应用［J］.国际眼科杂志，2015，15(5)：880-882.
［10］　LALLY D R，SHAH C P，HEIER J S.Vascular endothelial growth factor and diabetic macular edema［J］.Surv Ophthalmol，2016，61(6)：759-768.
［11］　JAMPOL L M，GLASSMAN A R，BRESSLER N M，WELLS J A，AYALA A R.Anti-vascular endothelial growth factor comparative effectiveness trial for diabetic macular edema：Additional efficacy post hoc analyses of a randomized clinical trial［J］.JAMA Ophthalmol，2016，134(12)：3698.
［12］　MOSHFEGHI D M，KAISER P K，MICHELS S，MIDENA E，KITCHENS J W，PRENNER J L，et al.The role of anti-VEGF therapy in the treatment of diabetic macular edema［J］.Ophthalmic Surg Lasers Imaging Retina，2016，47(6 Suppl)：S4-S14.
［13］　HUANG J Q.Clinical observation of compoxip injection in the treatment of diabetic cataract after phacoemulsification［J］.Diabetes N World，2016,(11)：60-62.
黄继琴.白内障超声乳化摘出术后康柏西普注射治疗糖尿病性白内障的临床观察［J］.糖尿病新世界，2016,（11）：60-62.

相似文献/References:

[1]邵东平 刘斐 朱春玲.非接触广角观察系统在白内障联合玻璃体视网膜手术中的应用[J].眼科新进展,2013,33(7):000.
[2]李保江.2.2mm微切口超声乳化白内障手术的临床疗效观察[J].眼科新进展,2014,34(6):564.[doi:10.13389/j.cnki.rao.2014.0154]
[3]徐欢欢,顾耀武,赵长霖,等.白内障超声乳化术后囊袋收缩综合征的临床分析[J].眼科新进展,2015,35(1):071.[doi:10.13389/j.cnki.rao.2015.0020]
　XU Huan-Huan,GU Yao-Wu,ZHAO Chang-Lin,et al.Clinical analysis of capsule contraction syndrome following cataract phacoemulsification surgery[J].Recent Advances in Ophthalmology,2015,35(11):071.[doi:10.13389/j.cnki.rao.2015.0020]
[4]苟文军,杨旭,方晏红,等. 超声乳化联合小梁切除术或房角分离术治疗合并白内障的慢性原发性闭角型青光眼[J].眼科新进展,2015,35(9):884.[doi:10.13389/j.cnki.rao.2015.0242]
　GOU Wen-Jun,YANG Xu,FANG Yan-Hong,et al. Phacoemulsification with trabeculectomy or goniosyn-echialysis for chronic primary angle-closure glaucoma with cataract[J].Recent Advances in Ophthalmology,2015,35(11):884.[doi:10.13389/j.cnki.rao.2015.0242]
[5]张娣,张玲,杨静,等.玻璃体内注射康柏西普联合手术及全视网膜光凝治疗新生血管性青光眼[J].眼科新进展,2015,35(12):1170.[doi:10.13389/j.cnki.rao.2015.0320]
　ZHANG Di,ZHANG Ling,YANG Jing,et al.Intravitreal injection of conbercept combined with operation and panretinal photocoagulation for neovascular glaucoma[J].Recent Advances in Ophthalmology,2015,35(11):1170.[doi:10.13389/j.cnki.rao.2015.0320]
[6]李娜,张杰,高荣玉,等.单次注射康柏西普治疗渗出型AMD患者RPE隆起面积与容积变化[J].眼科新进展,2016,36(2):172.[doi:10.13389/j.cnki.rao.2016.0047]
　LI Na,ZHANG Jie,GAO Rong-Yu,et al.Changes of retinal pigment epithelium uplift area and volume in exudative age-related macular degeneration after once injection of conbercept[J].Recent Advances in Ophthalmology,2016,36(11):172.[doi:10.13389/j.cnki.rao.2016.0047]
[7]王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性[J].眼科新进展,2016,36(5):471.[doi:10.13389/j.cnki.rao.2016.0126]
　WANG Chen,LI Dong-Hao,WEN Yi-Yi.Intravitreal injection of conbercept combined with selective peripheral retinal photocoagulation for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(11):471.[doi:10.13389/j.cnki.rao.2016.0126]
[8]王玮,徐玲娟,蔡苏博,等.角膜基质及结膜下单次注射康柏西普治疗角膜新生血管的疗效及安全性[J].眼科新进展,2016,36(8):725.[doi:10.13389/j.cnki.rao.2016.0192]
　WANG Wei,XU Lin-Juan,CAI Su-Bo,et al.Efficacy and safety of one dose intrastromal and subconjunctival conbercept injection for corneal neovascularization[J].Recent Advances in Ophthalmology,2016,36(11):725.[doi:10.13389/j.cnki.rao.2016.0192]
[9]史志洁,张金嵩,吕晓贝.玻璃体内注射康柏西普联合手术治疗伴玻璃体积血的新生血管性青光眼[J].眼科新进展,2016,36(8):751.[doi:10.13389/j.cnki.rao.2016.0200]
　SHI Zhi-Jie,ZHANG Jin-Song,LV Xiao-Bei.Intravitreal injection of conbercept and surgical treatment for neovascular glaucoma combined with vitreous hemorrhage[J].Recent Advances in Ophthalmology,2016,36(11):751.[doi:10.13389/j.cnki.rao.2016.0200]
[10]罗顺利,许泽广,梁春正.复合式小梁切除术联合康柏西普治疗新生血管性青光眼[J].眼科新进展,2016,36(11):1076.[doi:10.13389/j.cnki.rao.2016.0287]
　LUO Shun-Li,XU Ze-Guang,LIANG Chun-Zheng.Compound trabeculectomy with conbercept for neovascular glaucoma[J].Recent Advances in Ophthalmology,2016,36(11):1076.[doi:10.13389/j.cnki.rao.2016.0287]

备注/Memo

备注/Memo:
武汉市卫生计生委科研基金资助项目(编号：WX17C01、WX16C35、WX15B18)
更新日期/Last Update: 2019-11-18